Initiator Pharma signs screening agreement with the US National Institute on Drug Abuse to evaluate anti-addictive properties of preclinical assets

PRESS RELEASE

September 17, 2021

Initiator Pharma A/S, a clinical-stage Life Science company, today announced that it has signed a screening agreeement with the National Institute on Drug Abuse (NIDA) in the USA in order to investigate the potential benefits of the company’s preclinical assets IPDP2015 and IPNP2015 for improved treatment of addiction.

Initiator Pharma has signed a screening agreement with the National Institute on Drug Abuse (NIDA), www.nida.nih.gov, part of the National Institutes of Health (NIH), to evaluate the pharmacology of IPDP2015 and IPPD2015 to study their potential as treatments for stimulant addiction.  Specifically, NIDA’s Addiction Treatment Discovery Program will work closely with the company to determine the effects of IPDP2015 and IPPD2015 on cocaine- and methamphetamine-related behaviors using established preclinical rodent models through its contract resources.    

"Drug use and addiction is a devastating global challenge with significant social and financial implications for society, and especially for people with substance use disorders and their close relatives. This is a unique opportunity to generate value, creating and supportive preclinical data for our discovery assets," said Claus Elsborg Olesen, CEO at Initiator Pharma. "In this collaboration, NIDA will perform the studies at no cost to the company while Initiator Pharma will maintain all rights to the assets and to use of the data. This is in line with our strategy of advancing our pipeline assets through collaborations with both innovative academic and governmental research groups."

For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO

Phone: +45 6126 0035

E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT). Read more on www.initiatorpharma.com.